tiprankstipranks
Trending News
More News >
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H (HK:1541)
:1541
Hong Kong Market

ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H (1541) Revenue

Compare
3 Followers

ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H Revenue

ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H had a revenue of 44.01M in the quarter ending Jun 30, 2025, with -44.16%. This bring the company's revenue in the last twelve months to 122.83M, Decreased 54.43%. In the fiscal year ending Dec 31, 2024, ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H had annual revenue of 74.15M with 19109.59% growth.
Revenue (ttm)
122.83M
Revenue Growth
29639.67%
P/S Ratio
69.62
Revenue/Employee
HK$475,314
Employees
156
Market Cap
HK$5.16B

Revenue Chart

Revenue History
Fiscal End Date
Revenue
Change
Growth
Dec 31, 2024
74.15M73.76M+19,209.64%
Dec 31, 2023
386.00K-5.30M+6.78%
Dec 31, 2022
5.69M-8.12M+41.21%
Dec 31, 2021
13.81M